Provention Bio, Inc. (OTC:PRVB)
Industry: Basic Materials

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-300, an anti-TLR3 mAb, which is in Phase Ib clinical trial for the treatment of ulcerative colitis; PRV-3279, which is in phase Ib/IIa for the treatment of lupus; PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D; and PRV-015, which is in phase IIb for the treatment of gluten-free diet non-responding celiac disease. The company has a licensing and co-development agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.

Current Quote*
Last: $10.980
Change: -0.460
Book: $9.198
Volume: 574,165

As Of: 06/14 13:23 ET
*Quotes delayed by 20min.

Graphs for PRVB

3 Month Graph

6 Month Graph

1 Year Graph